Trial · NCT03503773

The TARGET BP OFF-MED Trial

NCT03503773, Phase 2, Completed, Ablative Solutions, Inc.; results first posted 2024-10-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The TARGET BP OFF-MED Trial. Trials, record NCT03503773. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03503773

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The TARGET BP OFF-MED Trial
NCT number: NCT03503773
Status: Completed
Phases: Phase 2
Enrollment: 350 participants, actual
Lead sponsor: Ablative Solutions, Inc.
Conditions: Hypertension, Hypertension,Essential
Interventions: Alcohol, Sham control
First posted: 2018-04-20
Last updated: 2025-05-14
Results first posted: 2024-10-04

Source ClinicalTrials.gov

Registered outcomes26

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Changes in Systolic Ambulatory Blood Pressure	Baseline to 8 weeks post-treatment	Change from baseline in mean 24-hour ambulatory systolic blood pressure
Secondary	Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months	6 months	Change from baseline in mean 24-hour ambulatory systolic blood pressure from baseline to 6 months
Secondary	Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months	12 months	Change from baseline in mean 24-hour systolic blood pressure at 12 months post-procedure
Secondary	Change in Office SBP at 8 Weeks	8 weeks	Change from Baseline in mean office SBP to Week 8
Secondary	Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks	8 weeks	Change from baseline in mean 24-hour ambulatory diastolic blood pressure and 8 weeks post-procedure
Secondary	Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months	6 months	Change from baseline in mean 24-hour ambulatory diastolic blood pressure at 6 months post-procedure
Secondary	Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months	12 months	Change from baseline in mean 24-hour diastolic blood pressure 12 months post-procedure
Secondary	Number of Participants With Major Adverse Events (MAEs)	30 days post procedure	Number of participants with major adverse events (MAEs) 30 days post-procedure
Secondary	Use of Antihypertensive Medication(s)	8 weeks	Use of antihypertensive medication at 8 weeks
Secondary	Change in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks	8 weeks	Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 8 Weeks

1 to 10 of 26Source ClinicalTrials.gov

See all 26 registered outcomes

Outcomes26

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Changes in Systolic Ambulatory Blood Pressure	Baseline to 8 weeks post-treatment	mmHg	MEAN
SECONDARY	Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months	6 months	mmHg	MEAN
SECONDARY	Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months	12 months	mmHg	MEAN
SECONDARY	Change in Office SBP at 8 Weeks	8 weeks	mmHg	MEAN
SECONDARY	Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks	8 weeks	mmHg	MEAN
SECONDARY	Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months	6 months	mmHg	MEAN
SECONDARY	Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months	12 months	mmHg	MEAN
SECONDARY	Number of Participants With Major Adverse Events (MAEs)	30 days post procedure	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Use of Antihypertensive Medication(s)	8 weeks	medications	MEAN
SECONDARY	Change in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks	8 weeks	mmHg	MEAN

1 to 10 of 26Source ClinicalTrials.gov

See all 26 outcomes

Results by group98

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Changes in Systolic Ambulatory Blood Pressure	Sham Control Arm		-1.4	Standard Deviation 8.6	mmHg
Changes in Systolic Ambulatory Blood Pressure	Treatment Arm:		-2.9	Standard Deviation 7.4	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months	Sham Control Arm	Mean 24-Hour Ambulatory Systolic Blood Pressure	135.1	Standard Deviation 11.7	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months	Treatment Arm:	Mean 24-Hour Ambulatory Systolic Blood Pressure	134.1	Standard Deviation 11.6	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months	Sham Control Arm	Change from baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure	-13.4	Standard Deviation 12.9	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months	Treatment Arm:	Change from baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure	-13.9	Standard Deviation 11.6	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months	Sham Control Arm	Mean 24-hour SBP	133.7	Standard Deviation 11.3	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months	Treatment Arm:	Mean 24-hour SBP	137.6	Standard Deviation 11.4	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months	Sham Control Arm	Change from baseline in mean 24-hour SBP	-15.9	Standard Deviation 13.1	mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months	Treatment Arm:	Change from baseline in mean 24-hour SBP	-10.6	Standard Deviation 11.5	mmHg

1 to 10 of 98Source ClinicalTrials.gov

See all 98 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Sham Control Arm	56
Overall Study	STARTED	Treatment Arm:	50
Overall Study	COMPLETED	Sham Control Arm	44
Overall Study	COMPLETED	Treatment Arm:	43
Overall Study	NOT COMPLETED	Sham Control Arm	12
Overall Study	NOT COMPLETED	Treatment Arm:	7

Source ClinicalTrials.gov

Adverse events272

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Oedema peripheral	General disorders	Sham Control Arm	3	56	3
other	Oedema peripheral	General disorders	Treatment Arm:	1	50	1
other	Nasopharyngitis	Infections and infestations	Sham Control Arm	4	56	4
other	Nasopharyngitis	Infections and infestations	Treatment Arm:	2	50	2
other	Post procedural haematoma	Injury, poisoning and procedural complications	Sham Control Arm	4	56	4
other	Post procedural haematoma	Injury, poisoning and procedural complications	Treatment Arm:	6	50	6
other	Blood pressure increased	Investigations	Sham Control Arm	3	56	3
other	Blood pressure increased	Investigations	Treatment Arm:	2	50	2
other	Glomerular filtration rate decreased	Investigations	Sham Control Arm	5	56	5
other	Glomerular filtration rate decreased	Investigations	Treatment Arm:	2	50	2

1 to 10 of 272Source ClinicalTrials.gov

See all 272 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sham Control Arm	0	56
Total, all-cause mortality	Treatment Arm:	0	50
Total, other adverse events	Sham Control Arm	42	56
Total, other adverse events	Treatment Arm:	41	50
Total, serious adverse events	Sham Control Arm	9	56
Total, serious adverse events	Treatment Arm:	7	50

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
32958438	DERIVED	PubMed
37427416	BACKGROUND	PubMed
39526682	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Treatment Arm: vs Sham Control Arm: Number of Participants With Major Adverse Events (MAEs)	Trial comparisons
Treatment Arm: vs Sham Control Arm: deaths from any cause	Trial comparisons
Treatment Arm: vs Sham Control Arm: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03503773

GET https://conductscience.org/api/trials/v1/NCT03503773/registered?page=2

API reference For AI assistants